Is it safe to use Vistaril (hydroxyzine) in a patient with supraventricular tachycardia (SVT)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Vistaril (Hydroxyzine) Should Be Avoided in Patients with SVT Due to Significant Cardiac Risk

Hydroxyzine is contraindicated or should be used with extreme caution in patients with supraventricular tachycardia due to documented risks of QT prolongation, torsade de pointes, and paradoxical induction of SVT episodes.

Critical Safety Concerns

The FDA drug label explicitly warns that hydroxyzine causes QT prolongation and torsade de pointes, particularly in patients with pre-existing cardiac conditions 1. The label specifically mandates caution in patients with:

  • Recent myocardial infarction
  • Uncompensated heart failure
  • Bradyarrhythmias
  • Concomitant use of antiarrhythmic drugs

Direct Evidence of Harm

Most concerning is a documented case of hydroxyzine directly triggering SVT in a 9-year-old patient who experienced supraventricular tachycardia at clinical doses, with recurrent palpitations over 5 months that completely resolved after discontinuing the medication 2. This represents the only published case of hydroxyzine-induced SVT, but it demonstrates a clear causal relationship.

Additionally, a 2023 case report documented hydroxyzine-induced torsade de pointes in a patient with an ICD, requiring intubation and multiple antiarrhythmic agents to control 3. A 2026 case series analyzing psychotropic safety in SSS patients specifically identified hydroxyzine as a cardiac risk requiring discontinuation or dose restriction due to QT prolongation concerns 4.

Guideline-Based Management of SVT

The 2015 ACC/AHA/HRS guidelines for SVT management recommend specific evidence-based therapies 5:

Acute treatment hierarchy:

  1. Vagal maneuvers (first-line, 27.7% success)
  2. Intravenous adenosine (95% effective for AVNRT)
  3. IV beta-blockers, diltiazem, or verapamil
  4. Synchronized cardioversion if pharmacotherapy fails

Notably, hydroxyzine appears nowhere in these comprehensive SVT management guidelines, which extensively detail appropriate and inappropriate medications.

Drug Interaction Concerns

If a patient with SVT is on antiarrhythmic therapy, hydroxyzine creates dangerous interactions 1:

  • Class IA antiarrhythmics (quinidine, procainamide): additive QT prolongation
  • Class III antiarrhythmics (amiodarone, sotalol): compounded arrhythmogenic risk
  • Beta-blockers and calcium channel blockers: potential for excessive cardiac depression

The 2020 ESC guidelines emphasize avoiding medications that prolong QT interval in SVT patients 6.

Clinical Algorithm for Decision-Making

If hydroxyzine is being considered for anxiety/sedation in an SVT patient:

  1. Obtain baseline ECG - measure QTc interval

    • If QTc >450 ms (men) or >470 ms (women): absolute contraindication
  2. Assess cardiac risk factors:

    • Active SVT episodes
    • Structural heart disease
    • Electrolyte abnormalities (hypokalemia, hypomagnesemia)
    • Concomitant QT-prolonging drugs
    • If any present: do not use hydroxyzine
  3. Consider safer alternatives:

    • For anxiety: SSRIs, buspirone, or low-dose benzodiazepines (short-term)
    • For sedation: mirtazapine (safest cardiac profile per 4)
    • For allergies: second-generation antihistamines (cetirizine, loratadine) with lower cardiac risk

Common Pitfalls to Avoid

  • Do not assume "low dose is safe" - the case report of TdP occurred with standard dosing 3
  • Do not use in elderly SVT patients - FDA label warns of increased sensitivity and cardiac risk 1
  • Do not combine with other sedatives - potentiates CNS depression and may mask cardiac symptoms 1
  • Do not use without cardiology consultation if patient has documented arrhythmia history

Bottom Line

Given the documented cases of hydroxyzine-induced SVT 2 and torsade de pointes 3, combined with FDA warnings about QT prolongation in cardiac patients 1 and complete absence from evidence-based SVT guidelines 5, hydroxyzine should be avoided entirely in patients with SVT. The risk-benefit ratio is unfavorable when safer alternatives exist for anxiety, sedation, or allergic conditions.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.